alongside chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC), AbbVie’s Skyrizi (risankizumab) for moderate to severe plaque psoriasis, and Ipsen’s Decapeptyl SR ...

and AbbVie's Skyrizi (risankizumab), as well as side effects of other therapies like topical corticosteroids. Dermavant's phase 3 trials of tapinarof – PSOARING 1 and 2 – showed that around 40 ...